European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Source Summary

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a ra